Open Access<p>Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study</p>
Author(s) -
Jie Qian,
Xueyan Zhang,
Bo Zhang,
Bo Yan,
Lin Wang,
Ping Gu,
Weimin Wang,
Huimin Wang,
Baohui Han
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s237968
Subject(s) - medicine , gefitinib , gastroenterology , erlotinib , adverse effect , common terminology criteria for adverse events , retrospective cohort study , liver function , liver function tests , hazard ratio , oncology , epidermal growth factor receptor , cancer , confidence interval
Hepatic injury is a common side effect following tyrosine kinase inhibitor (TKI) therapy and our understanding usually comes from clinical trials. In this retrospective study, we aimed to investigate the characteristics, risk factors and regimen-related differences of epidermal growth factor receptor (EGFR)-TKI-related hepatic toxicity in patients with advanced lung adenocarcinoma (LAD).